KR102625293B1 - Il-12 및 il-18로의 il-15-기반 융합 - Google Patents

Il-12 및 il-18로의 il-15-기반 융합 Download PDF

Info

Publication number
KR102625293B1
KR102625293B1 KR1020197029313A KR20197029313A KR102625293B1 KR 102625293 B1 KR102625293 B1 KR 102625293B1 KR 1020197029313 A KR1020197029313 A KR 1020197029313A KR 20197029313 A KR20197029313 A KR 20197029313A KR 102625293 B1 KR102625293 B1 KR 102625293B1
Authority
KR
South Korea
Prior art keywords
cells
fusion protein
domain
ser
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197029313A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126115A (ko
Inventor
워렌 디. 마커스
로버트 뉴먼
바이 리우
리징 유
린 콩
피터 로데
힝 씨. 웡
Original Assignee
알토 바이오사이언스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알토 바이오사이언스 엘엘씨 filed Critical 알토 바이오사이언스 엘엘씨
Priority to KR1020237042270A priority Critical patent/KR102739572B1/ko
Publication of KR20190126115A publication Critical patent/KR20190126115A/ko
Application granted granted Critical
Publication of KR102625293B1 publication Critical patent/KR102625293B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
KR1020197029313A 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합 Active KR102625293B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237042270A KR102739572B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762467623P 2017-03-06 2017-03-06
US62/467,623 2017-03-06
PCT/US2018/021220 WO2018165208A1 (en) 2017-03-06 2018-03-06 Il-15-based fusions to il-12 and il-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042270A Division KR102739572B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합

Publications (2)

Publication Number Publication Date
KR20190126115A KR20190126115A (ko) 2019-11-08
KR102625293B1 true KR102625293B1 (ko) 2024-01-15

Family

ID=63448011

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197029313A Active KR102625293B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합
KR1020257032318A Pending KR20250150164A (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합
KR1020237042270A Active KR102739572B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합
KR1020247039400A Active KR102867975B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257032318A Pending KR20250150164A (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합
KR1020237042270A Active KR102739572B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합
KR1020247039400A Active KR102867975B1 (ko) 2017-03-06 2018-03-06 Il-12 및 il-18로의 il-15-기반 융합

Country Status (8)

Country Link
US (8) US11129883B2 (enExample)
EP (1) EP3592778A4 (enExample)
JP (3) JP7191030B2 (enExample)
KR (4) KR102625293B1 (enExample)
CN (2) CN110785435B (enExample)
AU (1) AU2018231170B2 (enExample)
CA (2) CA3055318C (enExample)
WO (1) WO2018165208A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
KR102625293B1 (ko) * 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
CN107384859A (zh) * 2017-09-05 2017-11-24 四川新生命干细胞科技股份有限公司 一种高纯度nk细胞的分离培养方法
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン－１８バリアントとその利用法
CN119876019A (zh) * 2018-03-01 2025-04-25 格雷戈里奥马拉尼翁医院生物医学研究基金会 获得源自胸腺组织的调节性t细胞的方法及所述细胞作为细胞免疫疗法在免疫系统失调中的用途
WO2020023713A1 (en) * 2018-07-26 2020-01-30 Nantbio, Inc. Tri-cytokine txm compositions and methods
CN112996805A (zh) * 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2020051363A1 (en) * 2018-09-07 2020-03-12 Nantbio, Inc. Targeted il-12 treatments and methods to stimulate hank and nk92mi cells
AU2020294797B2 (en) * 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3117134A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. Ciml nk cells and methods therefor
CN113166726A (zh) 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
US20210008107A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. CIML NK cells and Methods Therefor
WO2021044439A1 (en) * 2019-09-08 2021-03-11 Immunoadaptive Cell Therapy Pvt Ltd. Inducible cytokine signals & methods for immunotherapy
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
EP4037700A2 (en) * 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021097227A1 (en) * 2019-11-14 2021-05-20 Altor Bioscience, Llc Il-15 fusion protein enhanced adoptive cell therapeutics
KR102400884B1 (ko) * 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US20240228964A9 (en) * 2021-03-03 2024-07-11 Immunitybio, Inc. Highly Potent M-CENK Cells And Methods
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
CN114853899B (zh) * 2021-11-02 2024-05-28 北京华奥玄德生物医药科技有限公司 一种il-12和il-18变体的融合蛋白及其制备方法和用途
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
US20240150422A1 (en) * 2022-07-18 2024-05-09 Onko-Innate Pty Ltd Il-12 fc fusion proteins and uses thereof
US20260048099A1 (en) * 2022-08-16 2026-02-19 The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service Synergistic interactions for improved cancer treatment
US20240327484A1 (en) * 2023-03-31 2024-10-03 Immunitybio, Inc. Il-12/il-18 superkines
JP2026524303A (ja) * 2023-06-14 2026-07-22 フューズ バイオセラピューティクス インコーポレイテッド 単一及び複数サイトカイン融合タンパク質、並びにその使用
WO2025068413A1 (en) * 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025184052A1 (en) * 2024-02-26 2025-09-04 Allegheny Singer Research Institute Interleukin 2 and interleukin 12 fusion proteins and methods of using
US20260027155A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
WO2026039841A1 (en) * 2024-08-16 2026-02-19 Board Of Regents, The University Of Texas System Tetra protein targeted killer engagers (tetrakes) in bladder cancer treatment
WO2026112610A1 (en) * 2024-11-25 2026-05-28 Immunitybio, Inc. Nk-92 cells with cytokine induced memory-like cytotoxicity and derivatives thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242025A1 (en) 2010-09-21 2014-08-28 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2511838C (en) 2002-12-31 2014-05-06 Schering Corporation Uses of mammalian cytokine; related reagents
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
PL3351261T3 (pl) * 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR102625293B1 (ko) 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242025A1 (en) 2010-09-21 2014-08-28 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Also Published As

Publication number Publication date
US11129883B2 (en) 2021-09-28
CA3216726C (en) 2025-08-05
WO2018165208A1 (en) 2018-09-13
KR20240173369A (ko) 2024-12-11
KR20250150164A (ko) 2025-10-17
JP2020508691A (ja) 2020-03-26
US20220062399A1 (en) 2022-03-03
US20250152686A1 (en) 2025-05-15
CN110785435A (zh) 2020-02-11
KR102739572B1 (ko) 2024-12-10
US12233116B2 (en) 2025-02-25
US20240252609A1 (en) 2024-08-01
US11872272B2 (en) 2024-01-16
AU2018231170A1 (en) 2019-09-19
JP7191030B2 (ja) 2022-12-16
CN117986384A (zh) 2024-05-07
US11612645B2 (en) 2023-03-28
CN110785435B (zh) 2024-01-23
EP3592778A1 (en) 2020-01-15
CA3055318A1 (en) 2018-09-13
JP7720950B2 (ja) 2025-08-08
KR20190126115A (ko) 2019-11-08
JP2024109747A (ja) 2024-08-14
US20190046623A1 (en) 2019-02-14
AU2018231170B2 (en) 2020-07-16
US20240100138A1 (en) 2024-03-28
US11975059B2 (en) 2024-05-07
CA3216726A1 (en) 2018-09-13
US11571470B2 (en) 2023-02-07
EP3592778A4 (en) 2021-01-13
US20250018020A1 (en) 2025-01-16
CA3055318C (en) 2025-11-25
JP2023027174A (ja) 2023-03-01
KR20230170821A (ko) 2023-12-19
US20220387570A1 (en) 2022-12-08
US20230248813A1 (en) 2023-08-10
KR102867975B1 (ko) 2025-10-14

Similar Documents

Publication Publication Date Title
KR102739572B1 (ko) Il-12 및 il-18로의 il-15-기반 융합
US12410224B2 (en) IL-15-based fusions to IL-7 and IL-21
US11318201B2 (en) Multimeric IL-15-based molecules
EP3464352B1 (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40014316B (en) Multimeric il-15-based molecules
HK40014316A (en) Multimeric il-15-based molecules
HK40007105B (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105A (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210219

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230519

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231030

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231206

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration